Gershenson DM - Search Results

1

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.

Merritt WM, Thaker PH, Landen CN Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK. Merritt WM, et al. Among authors: gershenson dm. Cancer Biol Ther. 2006 Oct;5(10):1357-60. doi: 10.4161/cbt.5.10.3225. Epub 2006 Oct 31. Cancer Biol Ther. 2006. PMID: 16969087

2

Serous ovarian tumors of low malignant potential with peritoneal implants.

Gershenson DM, Silva EG. Gershenson DM, et al. Cancer. 1990 Feb 1;65(3):578-85. doi: 10.1002/1097-0142(19900201)65:3<578::aid-cncr2820650332>3.0.co;2-n. Cancer. 1990. PMID: 2297647

3

Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy.

Robey SS, Silva EG, Gershenson DM, McLemore D, el-Naggar A, Ordonez NG. Robey SS, et al. Among authors: gershenson dm. Cancer. 1989 Mar 1;63(5):839-47. doi: 10.1002/1097-0142(19890301)63:5<839::aid-cncr2820630508>3.0.co;2-u. Cancer. 1989. PMID: 2644014

4

Molecular profile of advanced-stage transitional cell carcinoma of the ovary.

Gershenson DM, Baker VV, Price JE, Hung MC, El-Naggar AK, Tortolero-Luna G, Silva EG. Gershenson DM, et al. Am J Obstet Gynecol. 1997 Jul;177(1):120-5. doi: 10.1016/s0002-9378(97)70449-6. Am J Obstet Gynecol. 1997. PMID: 9240594

5

Ovarian serous borderline tumors with invasive peritoneal implants.

Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C. Gershenson DM, et al. Cancer. 1998 Mar 15;82(6):1096-103. Cancer. 1998. PMID: 9506355

6

Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation.

Silva EG, Tornos C, Deavers M, Kaisman K, Gray K, Gershenson D. Silva EG, et al. Gynecol Oncol. 1998 Nov;71(2):240-6. doi: 10.1006/gyno.1998.5153. Gynecol Oncol. 1998. PMID: 9826466

7

The current status of surgical staging of ovarian serous borderline tumors.

Lin PS, Gershenson DM, Bevers MW, Lucas KR, Burke TW, Silva EG. Lin PS, et al. Among authors: gershenson dm. Cancer. 1999 Feb 15;85(4):905-11. Cancer. 1999. PMID: 10091769

8

Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?

Mills GB, Schmandt R, Gershenson D, Bast RC. Mills GB, et al. Clin Cancer Res. 1999 Sep;5(9):2286-8. Clin Cancer Res. 1999. PMID: 10499594 No abstract available.

9

Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.

Wolf JK, Mills GB, Bazzet L, Bast RC Jr, Roth JA, Gershenson DM. Wolf JK, et al. Among authors: gershenson dm. Gynecol Oncol. 1999 Nov;75(2):261-6. doi: 10.1006/gyno.1999.5565. Gynecol Oncol. 1999. PMID: 10525383

10

A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.

Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT. Gershenson DM, et al. Cancer. 1999 Dec 1;86(11):2291-300. Cancer. 1999. PMID: 10590370 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

508 results

Search Page